STATCenter·
STAT+: Roivant is one of the savviest dealmakers in biotech. It also has a secret weapon
A Roivant lung disease drug has succeeded in a mid-stage study. But the drug’s origins are another fascinating aspect to the story.
Read at STAT →
Health · 1 sources covering this
STAT+: Roivant is one of the savviest dealmakers in biotech. It also has a secret weapon
A Roivant lung disease drug has succeeded in a mid-stage study. But the drug’s origins are another fascinating aspect to the story.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/9443a92cd6acea5db3e36795f795abb94fbd120a" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: Roivant is one of the savviest dealmakers in biotech. It also has a secret weapon"></iframe>
